Kinetics and seroprevalence of SARS-CoV-2 antibodies – a comparison of 3 different assays

  1. Elisabeth Kahre
  2. Lukas Galow
  3. Manja Unrath
  4. Luise Haag
  5. Judith Blankenburg
  6. Alexander H. Dalpke
  7. Christian Lück
  8. Reinhard Berner
  9. Jakob P. Armann
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Purpose

Comparing seroprevalence and antibody kinetics in three different commercially available assays for SARS-CoV-2.

Methods

Serostatus of COVID-19 patients was analyzed 5 months and 10 months after their infection, using three different assays: Diasorin LIAISON®, Euroimmun®, Abbott Diagnostics® ARCHITECT.

Results

Seropositivity at baseline differed significantly depending on the assay (Diasorin 81%, Euroimmun 83%, Abbott 59%). At follow-up antibody levels detected in the Diasorin assay were stable, while there was a significant loss in seropositivity in the Euroimmun and Abbott assays.

Conclusion

There are significant differences in SARS-CoV-2 antibody kinetics based on the specific assay used.

Trial registration number, date of registration

DRKS00022549, 29.07.2020 “retrospectively registered”

Related articles

Related articles are currently not available for this article.